

Bismuth Triflate-Chiral Bipyridine Complexes as Water-Compatible Chiral Lewis Acids

Shū Kobayashi,* Tsuyoshi Ogino, Haruka Shimizu, Shunpei Ishikawa, Tomoaki Hamada, and Kei Manabe

Graduate School of Pharmaceutical Sciences, The University of Tokyo, The HFRE Division ERATO, Japan Science and Technology Agency (JST), Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Supporting Information

Table of Contents	Pages
Experimental	S-1
Typical Experimental Procedures for the Hydroxymethylation	S-2
Characterization Data of the Hydroxymethylated Adducts	S-2
Crystallization of [BiBr ₃ • 1](H ₂ O) ₂ •DME Complexes	S-6
NMR Analyses of the Catalyst Structures	S-6
References	S-8


Experimental

General: Melting points were uncorrected. ¹H and ¹³C NMR spectra were recorded on a JEOL JNM-LA300, JNM-LA400, ECX-400 or ECX-600 spectrometer in CDCl₃ unless otherwise noted. Tetramethylsilane (TMS) served as an internal standard (δ = 0 ppm) for ¹H NMR and CDCl₃ as an internal standard (δ = 77.0 ppm) for ¹³C NMR. Preparative thin-layer chromatography was carried out using Wakogel B-5F. An aqueous solution of formaldehyde was purchased from Wako Pure Chemical Industries, Ltd.


Typical Experimental Procedure for the Hydroxymethylation of Propiophenone-derived Silicon Enolate: A mixture of Bi(OTf)₃ (14 mg, 0.020 mmol) and **1** (20 mg, 0.060 mmol) in DME (1 mL) was stirred at room temperature for 30 min to afford 20 mM of a catalyst solution. A reaction vessel charged with the catalyst solution (150 μ L) was cooled at 0 °C for 10 min, and an 81 mM solution of 2,2'-bipyridine in DME (185 μ L) was added. Then an aqueous solution of formaldehyde (129 mg, 35% w/w, 1.5 mmol) and the silicon enolate (62 mg, 0.30 mmol) were added to the mixture. The whole was stirred until the silicon enolate disappeared completely (checked by TLC). The reaction was quenched with saturated aqueous NaHCO₃. The resultant mixture was extracted with dichloromethane (3 times), and the combined organic layers were dried over anhydrous Na₂SO₄. The solvents were evaporated, and the residue was purified by preparative TLC (silica gel, hexane/ethyl acetate (2/1)) to give the hydroxymethylated adduct. The enantiomeric excess of the product was determined by chiral HPLC analysis.

Characterization Data of the Hydroxymethylated Adducts


(S)-3-Hydroxy-2-methyl-1-phenylpropan-1-one¹

 ¹H NMR (CDCl₃) δ 1.24 (d, 3H, J = 7.1 Hz), 2.35 (brs), 3.68 (ddq, 1H, J = 4.3, 7.0, 7.1 Hz), 3.80 (dd, 1H, J = 4.3, 11.1 Hz), 3.94 (dd, 1H, J = 7.0, 11.1 Hz), 7.48 (dd, 2H, J = 7.3, 8.5 Hz), 7.58 (t, 1H, J = 7.3 Hz), 7.97 (d, 2H, J = 8.5 Hz); ¹³C NMR (CDCl₃) δ 14.5, 42.9, 64.5, 128.4, 128.7, 133.3, 136.1, 204.4; HPLC (Daicel Chiralpak AD-H, hexane/*i*-PrOH = 19/1, flow rate = 1.0 mL/min) t_R = 17.5 min (major, *S*), t_R = 20.3 min (minor, *R*).

2-(Hydroxymethyl)-1-phenylbutan-1-one³


 ¹H NMR (CDCl₃) δ 0.95 (t, 3H, J = 7.4 Hz), 1.61-1.83 (m, 2H), 2.40 (brs), 3.52-3.58 (m, 1H), 3.84 (dd, 1H, J = 3.9, 11.0 Hz), 3.98 (dd, 1H, J = 6.8, 11.0 Hz), 7.45-7.50 (m, 2H), 7.56-7.60 (m, 1H), 7.95-7.97 (m, 2H); ¹³C NMR (CDCl₃) δ 11.8, 22.3, 49.5, 62.6, 128.3, 128.7, 133.2, 136.8, 204.6; IR (neat) 3435, 2966, 1678, 1043, 704 cm⁻¹; HRMS (ESI-TOF) calcd for C₁₁H₁₄O₂Na ([M+Na]⁺): 201.0891, found: 201.0889; [α]_D²⁴ -0.6 (*c* 0.75, CHCl₃) (91% ee); HPLC (Daicel Chiralpak AD-H, hexane/*i*-PrOH = 19/1, flow rate = 1.0 mL/min) t_R = 18.8 min (major), t_R = 22.4 min (minor).

3-(Hydroxy)-2-methyl-1-(4-methoxyphenyl)propan-1-one




^1H NMR (CDCl_3) δ 1.22 (d, 3H, $J = 7.1$ Hz), 2.60 (brs), 3.62 (ddq, 1H, $J = 4.3, 7.0, 7.1$ Hz), 3.78 (dd, 1H, $J = 4.3, 11$ Hz), 3.87 (s, 3H), 3.91 (dd, 1H, $J = 7.0, 11$ Hz), 6.95 (d, 2H, $J = 8.9$ Hz), 7.95 (d, 2H, $J = 8.9$ Hz); ^{13}C NMR (CDCl_3) δ 14.7, 42.4, 55.4, 64.6, 113.8, 129.0, 130.7, 163.6, 202.9; IR (neat) 3438, 2933, 1667, 1597, 1251, 1173, 1047, 975, 843 cm^{-1} ; MS m/z 194 (M^+); Anal. Calcd for $\text{C}_{11}\text{H}_{14}\text{O}_3$: C, 68.02; H, 7.27. found: C, 67.88; H, 7.33; $[\alpha]^{24}_{\text{D}} +4.2$ (c 1.5, CHCl_3) (88% ee); HPLC (Daicel Chiralpak AD-H, hexane/*i*-PrOH = 19/1, flow rate = 1.0 mL/min) $t_{\text{R}} = 30.7$ min (major), $t_{\text{R}} = 38.9$ min (minor).

3-(Hydroxy)-2-methyl-1-(4-chlorophenyl)propan-1-one




^1H NMR (CDCl_3) δ 1.21 (d, 3H, $J = 7.3$ Hz), 2.52 (brs), 3.62 (ddq, 1H, $J = 4.3, 7.2, 7.3$ Hz), 3.77 (dd, 1H, $J = 4.3, 11$ Hz), 3.87 (s, 3H), 3.93 (dd, 1H, $J = 7.2, 11$ Hz), 7.44 (d, 2H, $J = 8.5$ Hz), 7.90 (d, 2H, $J = 8.5$ Hz); ^{13}C NMR (CDCl_3) δ 14.4, 43.0, 64.4, 129.0, 129.8, 134.4, 139.7, 203.0; IR (neat) 3424, 2937, 1682, 1590, 1401, 1092, 976, 841 cm^{-1} ; MS m/z 198 (M^+); Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{ClO}_2$: C, 60.48; H, 5.58. found: C, 60.18; H, 5.85; $[\alpha]^{24}_{\text{D}} +4.1$ (c 1.05, CHCl_3) (89% ee); HPLC (Daicel Chiralpak AD-H, hexane/*i*-PrOH = 19/1, flow rate = 1.0 mL/min) $t_{\text{R}} = 18.6$ min (major), $t_{\text{R}} = 28.7$ min (minor).

3-Hydroxy-1-(2-methoxynaphthalen-6-yl)-2-methylpropan-1-one




^1H NMR (CDCl_3) δ 1.28 (d, 3H, $J = 6.9$ Hz), 2.60 (s, 1H), 3.78-3.86 (m, 2H), 3.93 (s, 3H), 3.98 (m, 1H), 7.13 (m, 1H), 7.20 (m, 1H), 7.75 (m, 1H), 7.83 (m, 1H), 7.98 (m, 1H), 8.40 (m, 1H); ^{13}C NMR (CDCl_3) δ 14.8, 42.7, 55.4, 64.7, 105.7, 119.7, 124.7, 127.2, 127.8, 130.1, 131.2, 131.4, 137.4, 159.8, 204.1; IR (neat) 3444, 1665, 1622, 1477, 1268, 1187, 1028 cm^{-1} ; HRMS (ESI-TOF) calcd for $\text{C}_{15}\text{H}_{17}\text{O}_3$ ($[\text{M}+\text{H}]^+$): 245.1178, found: 245.1166; $[\alpha]^{24}_{\text{D}} +2.3$ (c 1.84, CHCl_3) (92% ee); HPLC (Daicel Chiralcel OD, hexane/*i*-PrOH = 19/1, flow rate = 1.0 mL/min) $t_{\text{R}} = 30.7$ min (minor), $t_{\text{R}} = 36.6$ min (major).

2,3-Dihydro-2-(hydroxymethyl)-2-methylinden-1-one³




¹H NMR (CDCl₃) δ 1.26 (s, 3H), 2.91 (d, 1H, *J* = 7.2 Hz), 3.24 (d, 1H, *J* = 7.2 Hz), 3.64 (d, 1H, *J* = 11 Hz), 3.83 (d, 1H, *J* = 11 Hz), 7.35-7.41 (m, 1H), 7.45-7.48 (m, 1H), 7.59-7.64 (m, 1H), 7.64-7.77 (m, 1H); ¹³C NMR (CDCl₃) δ 20.7, 38.0, 50.8, 67.8, 124.2, 126.7, 127.5, 135.2, 135.8, 153.2, 211.1; IR (KBr) 3473, 2962, 2921, 2866, 1703 cm⁻¹; Mp 83-89 °C; Anal. calcd for C₁₁H₁₂O₂: C, 74.98; H, 6.86. found: C, 74.80; H, 7.05; [α]_D²⁴ +1.6 (*c* 0.95, CHCl₃) (88% ee); HPLC (Daicel Chiralcel OB-H, hexane/*i*-PrOH = 100/1, flow rate = 1.0 mL/min) *t*_R = 39.6 min (major), *t*_R = 50.0 min (minor).

3,4-Dihydro-2-(hydroxymethyl)-2-methylnaphthalen-1(2*H*)-one³




¹H NMR (CDCl₃) δ 1.23 (s, 3H), 1.78 (ddd, 1H, *J* = 3.7, 4.9, 13.4 Hz), 2.24 (ddd, 1H, *J* = 5.1, 12.0, 13.4 Hz), 2.77 (brs), 2.94 (ddd, 1H, *J* = 3.7, 5.1, 17.3 Hz), 3.15 (ddd, 1H, *J* = 4.9, 12.0, 17.3 Hz), 3.65 (d, 1H, *J* = 11.2 Hz), 3.74 (d, 1H, *J* = 11.2 Hz), 7.24-7.26 (m, 1H), 7.29-7.33 (m, 1H), 7.47-7.50 (m, 1H), 8.00-8.03 (m, 1H); ¹³C NMR (CDCl₃) δ 18.2, 25.0, 31.3, 46.3, 69.0, 126.7, 127.7, 128.7, 131.4, 133.6, 143.4, 204.0; IR (neat) 3456, 2931, 1678, 1047, 742 cm⁻¹; HRMS (ESI-TOF) calcd for C₁₂H₁₄O₂Na ([M+Na]⁺): 213.0891, found: 213.0881; [α]_D²⁴ -1.4 (*c* 1.3, CHCl₃) (95% ee); HPLC (Daicel Chiralcel OD, hexane/*i*-PrOH = 100/1, flow rate = 1.0 mL/min) *t*_R = 28.6 min (major), *t*_R = 34.3 min (minor).

2-Butyl-3,4-dihydro-2-(hydroxymethyl)naphthalen-1(2*H*)-one




¹H NMR (CDCl₃) δ; ¹³C NMR (CDCl₃) δ 13.9, 23.2, 24.9, 25.8, 28.0, 29.9, 49.5, 66.5, 126.7, 127.7, 128.7, 131.6, 133.5, 143.4, 204.4; IR (neat) 3443, 1672, 1458, 1227, 1053, 742 cm⁻¹; HRMS (ESI-TOF) calcd for C₁₅H₂₁O₂Na ([M+Na]⁺): 255.1356, found: 255.1362; [α]_D²⁴ -2.8 (*c* 0.75, CHCl₃) (93% ee); HPLC (Daicel Chiralcel OD, hexane/*i*-PrOH = 100/1, flow rate = 1.0 mL/min) *t*_R = 20.6 min (major), *t*_R = 23.6 min (minor).

(*R*)-2-(Hydroxymethyl)-2-methylcyclohexanone²




[(*R*)-1-Methyl-2-oxocyclohexyl]methyl benzoate³




¹H NMR (CDCl₃) δ 1.26 (s, 3H), 1.73-1.98 (m, 6H), 2.42-2.54 (m, 2H), 4.38 (d, 1H, *J* = 11.0 Hz), 4.46 (d, 1H, *J* = 11.0 Hz), 7.41-7.45 (m, 2H), 7.53-7.58 (m, 1H), 7.99-8.01 (m, 2H); ¹³C NMR (CDCl₃) δ 20.8, 21.0, 27.2, 36.4, 38.8, 48.9, 69.1, 128.3, 129.5, 130.0, 133.0, 166.3, 212.9; IR (neat) 2937, 1718, 1274, 1115, 714 cm⁻¹; Anal. calcd for C₁₅H₁₈O₃: C, 73.15; H, 7.37. found: C, 73.24; H, 7.54; [α]¹⁸_D -0.2 (*c* 0.50, CHCl₃) (for *R*, 77% ee); HPLC (Daicel Chiralpak AD-H, hexane/*i*-PrOH = 100/1, flow rate = 0.5 mL/min) *t*_R = 39.7 min (major, *R*), *t*_R = 42.3 min (minor, *S*).

2-Benzyl-2-(hydroxymethyl)cyclohexanone³



2-Benzyl-2-(hydroxymethyl)cyclopentanone

 ^1H NMR (CDCl_3) δ 1.56-1.88 (m, 3H), 1.94 (m, 1H), 2.11-2.31 (m, 2H), 2.41 (br, 1H), 2.81 (dd, 2H, $J = 13, 28$ Hz), 3.55 (m, 2H), 7.16 (m, 2H), 7.20-7.30 (m, 3H); ^{13}C NMR (CDCl_3) δ 19.0, 29.8, 37.9, 39.1, 54.3, 65.7, 126.6, 128.3, 130.2, 136.8, 224.5; IR (neat) 3438, 1727, 1160, 1053, 757, 705 cm^{-1} ; HRMS (ESI-TOF) calcd for $\text{C}_{10}\text{H}_{16}\text{O}_2\text{Na}$ ($[\text{M}+\text{Na}]^+$): 227.1043, found: 227.1040; $[\alpha]_D^{24} -4.5$ (c 0.85, CHCl_3) (79% ee); HPLC (Daicel Chiralpak AD-H, hexane/*i*-PrOH = 19/1, flow rate = 1.0 mL/min) $t_R = 15.1$ min (major), $t_R = 19.0$ min (minor).


Crystallization of $[\text{BiBr}_3 \cdot \mathbf{1}] \cdot (\text{H}_2\text{O})_2 \cdot \text{DME}$ complexes

Crystallization of $[\text{BiBr}_3 \cdot \mathbf{1}] \cdot (\text{H}_2\text{O})_2 \cdot \text{DME}$ was carried out as follows: To a yellow solution of BiBr_3 (20.2 mg, 45 μmol) in DME (20 μL) was added **1** (14.8 mg, 45 μmol) at room temperature. The solution was warmed to 75 $^\circ\text{C}$ (oil bath temperature). Then, a white precipitate was gradually formed, and was dissolved by addition of DME (630 μL). The resulting solution was allowed to stand at room temperature under DME vapor to give the crystals.


NMR analysis of the catalyst structure

NMR experiments were conducted to obtain some information about the catalyst structure when the $\text{Bi}(\text{OTf})_3$ -**1** ratio were 1:0.5, 1:1, 1:2 and 1:3 (Figure S-1). When the $\text{Bi}(\text{OTf})_3$ and **1** were combined at the ratio of 1:0.5, a signal at 5.49 ppm was dominant. On the other hand, another signal at 4.72 ppm increased when the ratio of **1** to $\text{Bi}(\text{OTf})_3$ increased, and finally the former signal disappeared when $\text{Bi}(\text{OTf})_3$ was combined with three equivalents of **1**. These results indicate that two equivalents of $\text{Bi}(\text{OTf})_3$ and one equivalent of **1** formed complex **3**, and that complex **4** consisting of one equivalent of $\text{Bi}(\text{OTf})_3$ and one equivalent of **1** was generated when excess amount of **1** was added (Scheme S-1).

Figure S-1. ^1H NMR analysis of the catalyst structure.



Scheme S-1.



Representative Procedure for NMR Experiments: $[\text{Bi}(\text{OTf})_3:\mathbf{1} = 1:1]$ A solution of $\text{Bi}(\text{OTf})_3$ (24 mg, 0.036 mmol) and **1** (12mg 0.036 mmol) in CD_3CN (900 μL) was stirred at 0 $^\circ\text{C}$ for 10 min. D_2O (100 μL) was added to the mixture, and the solution was stirred for 30 min at 0 $^\circ\text{C}$. NMR experiments were conducted at 0 $^\circ\text{C}$ using ECX-600 NMR spectrometer. The deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc. and used without further purification.

References

- (1) Manabe, K.; Ishikawa, S.; Hamada, T.; Kobayashi, S. *Tetrahedron* **2003**, *59*, 10439.
- (2) Miyaoka, H.; Kajiwara, Y.; Hara, M.; Suma, A.; Yamada, Y. *Tetrahedron: Asymmetry* **1999**, *10*, 3189.
- (3) Ishikawa, S.; Hamada, T.; Manabe, K.; Kobayashi, S. *J. Am. Chem. Soc.* **2004**, *126*, 12236.